ASX - By Stock
|
PER |
Re:
Ann: ANP raises A$7.3 million from Oversubscribed Placement
|
|
krispi
|
54 |
13K |
0 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
54
|
13K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Biopharma Notes
|
|
krispi
|
11 |
1.8K |
4 |
28/10/20 |
28/10/20 |
ASX - By Stock
|
11
|
1.8K
|
4
|
|
Charts
|
PER |
Re:
Chart
|
|
krispi
|
5.9K |
2.2M |
3 |
03/07/20 |
03/07/20 |
Charts
|
5.9K
|
2.2M
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
krispi
|
5.9K |
2.2M |
4 |
02/07/20 |
02/07/20 |
Charts
|
5.9K
|
2.2M
|
4
|
|
ASX - By Stock
|
PER |
Re:
PPMD webinar
|
|
krispi
|
72 |
19K |
16 |
20/06/20 |
20/06/20 |
ASX - By Stock
|
72
|
19K
|
16
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Market Update and ACW to Participate in BIO Digital
|
|
krispi
|
108 |
30K |
1 |
16/06/20 |
16/06/20 |
ASX - By Stock
|
108
|
30K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations
|
|
krispi
|
222 |
81K |
0 |
10/06/20 |
10/06/20 |
ASX - By Stock
|
222
|
81K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
One approach to calculate the value of Presendin
|
|
krispi
|
3 |
2.0K |
4 |
22/05/20 |
22/05/20 |
ASX - By Stock
|
3
|
2.0K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations
|
|
krispi
|
222 |
81K |
7 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
222
|
81K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations
|
|
krispi
|
222 |
81K |
7 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
222
|
81K
|
7
|
|
ASX - By Stock
|
IXC |
Re:
One approach to calculate the value of Presendin
|
|
krispi
|
3 |
2.0K |
2 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
3
|
2.0K
|
2
|
|
ASX - By Stock
|
IXC |
One approach to calculate the value of Presendin
|
|
krispi
|
3 |
2.0K |
9 |
21/05/20 |
21/05/20 |
ASX - By Stock
|
3
|
2.0K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Thoughts on ATL1102 for DMD
|
|
krispi
|
5 |
2.0K |
0 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
5
|
2.0K
|
0
|
|
ASX - By Stock
|
PER |
Thoughts on ATL1102 for DMD
|
|
krispi
|
5 |
2.0K |
12 |
19/05/20 |
19/05/20 |
ASX - By Stock
|
5
|
2.0K
|
12
|
|
Charts
|
PER |
Re:
Chart
|
|
krispi
|
5.9K |
2.2M |
1 |
19/05/20 |
19/05/20 |
Charts
|
5.9K
|
2.2M
|
1
|
|
Charts
|
PER |
Re:
Chart
|
|
krispi
|
5.9K |
2.2M |
5 |
19/05/20 |
19/05/20 |
Charts
|
5.9K
|
2.2M
|
5
|
|
Political Debate
|
|
Re:
China suspends four Australian beef plants in trade tensions
|
|
krispi
|
239 |
40K |
0 |
12/05/20 |
12/05/20 |
Political Debate
|
239
|
40K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
7 |
09/05/20 |
09/05/20 |
ASX - By Stock
|
80
|
27K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
3 |
09/05/20 |
09/05/20 |
ASX - By Stock
|
80
|
27K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
4 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
80
|
27K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
7 |
08/05/20 |
08/05/20 |
ASX - By Stock
|
80
|
27K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
3 |
07/05/20 |
07/05/20 |
ASX - By Stock
|
80
|
27K
|
3
|
|
ASX - By Stock
|
ACW |
11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis
|
|
krispi
|
80 |
27K |
3 |
05/05/20 |
05/05/20 |
ASX - By Stock
|
80
|
27K
|
3
|
|
ASX - By Stock
|
IXC |
Fifty one capital podcast episode on Invex
|
|
krispi
|
5 |
1.7K |
4 |
23/04/20 |
23/04/20 |
ASX - By Stock
|
5
|
1.7K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Appendix 3G - Issue of Options
|
|
krispi
|
4 |
1.3K |
0 |
15/04/20 |
15/04/20 |
ASX - By Stock
|
4
|
1.3K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Appendix 4D and Half-year Report
|
|
krispi
|
16 |
85K |
4 |
27/02/20 |
27/02/20 |
ASX - By Stock
|
16
|
85K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Why IXC is a Strong BUY awaiting Phase 2 results in March 2020
|
|
krispi
|
46 |
18K |
3 |
23/02/20 |
23/02/20 |
ASX - By Stock
|
46
|
18K
|
3
|
|
ASX - By Stock
|
PER |
Re:
General Discussion re ANP
|
|
krispi
|
12 |
24K |
2 |
21/02/20 |
21/02/20 |
ASX - By Stock
|
12
|
24K
|
2
|
|
ASX - By Stock
|
SNT |
Re:
Realistic views pls
|
|
krispi
|
4 |
24K |
0 |
19/02/20 |
19/02/20 |
ASX - By Stock
|
4
|
24K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Results in DMD unlock value creation potential of ATL1102
|
|
krispi
|
93 |
54K |
15 |
12/02/20 |
12/02/20 |
ASX - By Stock
|
93
|
54K
|
15
|
|
ASX - By Stock
|
SNT |
Re:
Bell Potter research on PXS
|
|
krispi
|
2 |
12K |
7 |
12/02/20 |
12/02/20 |
ASX - By Stock
|
2
|
12K
|
7
|
|
ASX - By Stock
|
SNT |
Re:
We are reaching book value soon
|
|
krispi
|
3 |
5.9K |
4 |
01/02/20 |
01/02/20 |
ASX - By Stock
|
3
|
5.9K
|
4
|
|
ASX - By Stock
|
SNT |
We are reaching book value soon
|
|
krispi
|
3 |
5.9K |
5 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
3
|
5.9K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Why IXC is a Strong BUY awaiting Phase 2 results in March 2020
|
|
krispi
|
46 |
18K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
46
|
18K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
XanaHES and its implications for Actinogen
|
|
krispi
|
10 |
118K |
3 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
10
|
118K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
XanaHES and its implications for Actinogen
|
|
krispi
|
10 |
118K |
2 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
10
|
118K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Why IXC is a Strong BUY awaiting Phase 2 results in March 2020
|
|
krispi
|
46 |
18K |
2 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
46
|
18K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Why IXC is a Strong BUY awaiting Phase 2 results in March 2020
|
|
krispi
|
46 |
18K |
1 |
30/01/20 |
30/01/20 |
ASX - By Stock
|
46
|
18K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Invex - A
|
|
krispi
|
4 |
2.0K |
0 |
29/01/20 |
29/01/20 |
ASX - By Stock
|
4
|
2.0K
|
0
|
|
ASX - By Stock
|
IXC |
Invex - A
|
|
krispi
|
4 |
2.0K |
0 |
29/01/20 |
29/01/20 |
ASX - By Stock
|
4
|
2.0K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
XanaHES and its implications for Actinogen
|
|
krispi
|
10 |
118K |
4 |
29/01/20 |
29/01/20 |
ASX - By Stock
|
10
|
118K
|
4
|
|
ASX - By Stock
|
ACW |
XanaHES and its implications for Actinogen
|
|
krispi
|
10 |
118K |
29 |
29/01/20 |
29/01/20 |
ASX - By Stock
|
10
|
118K
|
29
|
|
ASX - By Stock
|
ZNO |
Re:
Ann: Zoono Signs Deal with Chinese Group
|
|
krispi
|
286 |
134K |
14 |
23/12/19 |
23/12/19 |
ASX - By Stock
|
286
|
134K
|
14
|
|